Year archive

Can-Fite BioPharma Ltd. — 2025 filings

All 144 regulatory filings released by Can-Fite BioPharma Ltd. (CANF) in 2025, sourced directly from the official regulator.

144 Filings

2025 Period

2025 filings (144)

Filing	Released	Lang
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction Regulatory Filings	2025-12-29	English
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction Report Publication Announcement	2025-12-29	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-12-29	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-12-23	English
Other Report or Announcement Regulatory Filings	2025-12-23	English
Other Report or Announcement Share Issue/Capital Change	2025-12-23	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-12-16	English
Can-Fite Provides Update on Clinical and Financial Status Regulatory Filings	2025-12-16	English
Can-Fite Provides Update on Clinical and Financial Status Report Publication Announcement	2025-12-16	English
PROSPECTUS SUPPLEMENT Regulatory Filings	2025-11-21	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-11-21	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-11-20	English
CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - 6ל Regulatory Filings	2025-11-20	English
CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - 6ל Regulatory Filings	2025-11-20	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-11-18	English
6K- Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson Regulatory Filings	2025-11-18	Hebrew (modern)
6K- Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson Audit Report / Information FY 2025	2025-11-18	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-11-10	English
Other Report or Announcement Declaration of Voting Results & Voting Rights Announcements	2025-11-10	English
Other Report or Announcement Declaration of Voting Results & Voting Rights Announcements	2025-11-10	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-11-03	English
Other Report or Announcement AGM Information	2025-11-03	English
Other Report or Announcement Report Publication Announcement Q4 2025	2025-11-03	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-10-03	English
Other Report or Announcement Proxy Solicitation & Information Statement	2025-10-03	English
Other Report or Announcement Report Publication Announcement FY 2025	2025-10-03	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-09-15	English
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson Regulatory Filings	2025-09-15	English
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson Regulatory Filings	2025-09-15	English
Regulatory Filings 2025 Regulatory Filings	2025-09-12	English
Regulatory Filings 2025 Regulatory Filings	2025-09-12	English
Other Report or Announcement Transaction in Own Shares	2025-09-08	English
Other Report or Announcement Transaction in Own Shares	2025-09-08	English
POST-EFFECTIVE AMENDMENT NO. 9 TO FORM F-1 Regulatory Filings	2025-09-08	English
POST-EFFECTIVE AMENDMENT NO. 9 TO FORM F-1 Regulatory Filings	2025-09-08	English
Other Report or Announcement Capital/Financing Update	2025-09-08	English
Other Report or Announcement Regulatory Filings	2025-09-08	English
POST-EFFECTIVE AMENDMENT NO. 8 TO FORM F-1 Regulatory Filings	2025-09-08	English
POST-EFFECTIVE AMENDMENT NO. 8 TO FORM F-1 Regulatory Filings	2025-09-08	English
POST-EFFECTIVE AMENDMENT NO. 7 TO FORM F-1 Regulatory Filings	2025-08-28	English
POST-EFFECTIVE AMENDMENT NO. 7 TO FORM F-1 Regulatory Filings	2025-08-28	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-08-28	English
Financial results for the six months ended June 30, 2025 and updates on drug development programs Interim / Quarterly Report H1 2025	2025-08-28	English
Financial results for the six months ended June 30, 2025 and updates on drug development programs Report Publication Announcement	2025-08-28	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-07-30	English
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone Regulatory Filings	2025-07-30	English
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone Report Publication Announcement	2025-07-30	English
Prospectus Filed pursuant to Rule 424(b)(4) Capital/Financing Update	2025-07-29	English
Prospectus Filed pursuant to Rule 424(b)(4) Report Publication Announcement	2025-07-29	English
6-K: Report of foreign issuer Regulatory Filings	2025-07-29	English
6-K: Report of foreign issuer Report Publication Announcement	2025-07-29	English
PROSPECTUS Regulatory Filings	2025-07-29	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-07-29	English
Regulatory Filings 2025 Regulatory Filings	2025-07-29	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-07-28	English
Other Report or Announcement Capital/Financing Update	2025-07-28	English
Other Report or Announcement Capital/Financing Update	2025-07-28	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-07-28	English
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia Regulatory Filings	2025-07-28	English
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia Report Publication Announcement	2025-07-28	English
Other Report or Announcement Capital/Financing Update	2025-07-25	English
Other Report or Announcement Report Publication Announcement	2025-07-25	English
AMENDMENT NO. 1 TO FORM F-1 Regulatory Filings	2025-07-25	English
Regulatory Filings 2025 Regulatory Filings	2025-07-24	English
Regulatory Filings 2025 Regulatory Filings	2025-07-24	English
REGISTRATION STATEMENT Regulatory Filings	2025-07-23	English
Other Report or Announcement Capital/Financing Update	2025-07-23	English
Other Report or Announcement Regulatory Filings	2025-07-23	English
Regulatory Filings 2025 Regulatory Filings	2025-07-22	English
Regulatory Filings 2025 Regulatory Filings	2025-07-17	English
Regulatory Filings 2025 Regulatory Filings	2025-07-15	English
Regulatory Filings 2025 Regulatory Filings	2025-07-09	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-06-30	English
Other Report or Announcement Regulatory Filings	2025-06-30	English
Other Report or Announcement AGM Information	2025-06-30	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-06-23	English
Annual General Meeting was adjourned for June 30, 2025 due to lack of quorum AGM Information	2025-06-23	English
Annual General Meeting was adjourned for June 30, 2025 due to lack of quorum AGM Information	2025-06-23	English
Regulatory Filings 2025 Regulatory Filings	2025-06-17	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-06-16	English
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston Regulatory Filings	2025-06-16	English
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston Regulatory Filings	2025-06-16	English
Immediate Report of Meeting AGM Information	2025-05-16	English
Immediate Report of Meeting AGM Information	2025-05-16	English
Immediate Report of Meeting AGM Information	2025-05-16	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-05-16	English
PROSPECTUS SUPPLEMENT Regulatory Filings	2025-05-09	English
ATM Prospectus Supplement Capital/Financing Update	2025-05-09	English
ATM Prospectus Supplement Report Publication Announcement	2025-05-09	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-05-05	English
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis Regulatory Filings	2025-05-05	English
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis Report Publication Announcement	2025-05-05	English
Major Shareholding Notification 2025 Major Shareholding Notification	2025-04-23	English
Regulatory Filings 2025 Regulatory Filings	2025-04-18	English
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients Regulatory Filings	2025-04-17	English
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients Report Publication Announcement	2025-04-17	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-04-17	English
Major Shareholding Notification 2025 Major Shareholding Notification	2025-04-16	English
PROSPECTUS SUPPLEMENT-750,000,000 Ordinary Shares Represented by 2,500,000 American Depositary Shares Capital/Financing Update	2025-04-15	English
PROSPECTUS SUPPLEMENT-750,000,000 Ordinary Shares Represented by 2,500,000 American Depositary Shares Capital/Financing Update	2025-04-15	English
FORM 6-K-securities purchase agreement Regulatory Filings	2025-04-15	English
FORM 6-K-securities purchase agreement Report Publication Announcement	2025-04-15	English
PROSPECTUS SUPPLEMENT Regulatory Filings	2025-04-15	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-04-15	English
Can-Fite BioPharma has entered into definitive agreements to receive upon closing gross proceeds of $3 million in a registered direct offering Regulatory Filings	2025-04-14	English
Can-Fite BioPharma has entered into definitive agreements to receive upon closing gross proceeds of $3 million in a registered direct offering Report Publication Announcement	2025-04-14	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-04-14	English
POST-EFFECTIVE AMENDMENT NO. 8 TO FORM F-1 Regulatory Filings	2025-04-14	English
Post Effective Amendment Transaction in Own Shares	2025-04-14	English
Post Effective Amendment Regulatory Filings	2025-04-14	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-04-14	English
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships Regulatory Filings	2025-04-14	English
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships Report Publication Announcement	2025-04-14	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-04-14	English
ANNUAL REPORT Annual Report FY 2024	2025-04-14	English
Can-Fite Reports 2024 Financial Results and Clinical Update-FORM 6-K Earnings Release FY 2024	2025-04-14	English
Can-Fite Reports 2024 Financial Results and Clinical Update-FORM 6-K Report Publication Announcement	2025-04-14	English
2024 20-F Annual Report FY 2024	2025-04-14	English
2024 20-F Report Publication Announcement	2025-04-14	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-03-24	English
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol Regulatory Filings	2025-03-24	English
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol Report Publication Announcement	2025-03-24	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-03-20	English
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market Regulatory Filings	2025-03-20	English
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market Report Publication Announcement	2025-03-20	English
FORM 6-K Regulatory Filings	2025-03-19	English
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson Regulatory Filings	2025-03-19	English
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson Report Publication Announcement	2025-03-19	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-03-18	English
FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient Regulatory Filings	2025-03-18	English
FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient Report Publication Announcement	2025-03-18	English
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits Regulatory Filings	2025-03-03	English
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits Report Publication Announcement	2025-03-03	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-03-03	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-02-18	English
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite’s Namodenoson. Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 203 Regulatory Filings	2025-02-18	English
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite’s Namodenoson. Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 203 Report Publication Announcement	2025-02-18	English
Major Shareholding Notification 2025 Major Shareholding Notification	2025-02-14	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-02-05	English
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025. In addition, the Company has posted to its website an updated corporate presentation Regulatory Filings	2025-02-05	English
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025. In addition, the Company has posted to its website an updated corporate presentation Report Publication Announcement	2025-02-05	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2025-01-27	English
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug Regulatory Filings	2025-01-27	English
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug Report Publication Announcement	2025-01-27	English

Filings by year

2026 72 filings
2025 144 filings
2024 140 filings
2023 170 filings
2022 110 filings
2021 151 filings
2020 315 filings
2019 251 filings
2018 150 filings
2017 166 filings
2016 178 filings
2015 160 filings
2014 129 filings
2013 34 filings
2012 2 filings